Non-Statin Medications for Hyperlipidemia Management

Introduction to Non-Statin Therapy

• Non-statin medications, such as ezetimibe and PCSK9 inhibitors, play a critical role as adjunctive therapy when statins alone are insufficient to reach LDL-C goals or as alternative therapy in statin-intolerant patients, as recommended by the American College of Cardiology 1

Hierarchy of Non-Statin Medications

• The American College of Cardiology recommends a clear hierarchy for non-statin medications in hyperlipidemia management, starting with maximally tolerated statin therapy, followed by ezetimibe, then PCSK9 inhibitors for high-risk patients not at goal, and finally bempedoic acid and other specialized therapies for specific conditions 1

Ezetimibe as First-Line Non-Statin Agent

• Ezetimibe provides 18-25% additional LDL-C reduction, as demonstrated in studies published in Arteriosclerosis, Thrombosis, and Vascular Biology, and has demonstrated cardiovascular benefit in the IMPROVE-IT trial with ~7% reduction in cardiovascular events 2
• Ezetimibe is available as a generic, improving cost-effectiveness, according to the American College of Cardiology 1

PCSK9 Inhibitors for High-Risk Patients

• PCSK9 inhibitors, such as evolocumab, achieve 50-65% reductions in LDL-C levels when added to statin therapy, representing a significant advancement in lipid management, and reduce lipoprotein(a) [Lp(a)] by up to 25%, increase HDL-C by approximately 4.5-6.8%, and reduce total cholesterol and apolipoprotein B, as reported by the American College of Cardiology 1, 3, 2
• PCSK9 inhibitors are generally safe with minimal side effects beyond occasional injection site reactions, and the evidence strongly supports their efficacy in reducing major cardiovascular events by approximately 15% in high-risk patients, as noted by the American College of Cardiology and the European Heart Journal 4, 5, 2

Bempedoic Acid as a Newer Non-Statin Option

• Bempedoic acid provides approximately 17% additional LDL-C reduction and is particularly useful in statin-intolerant patients with myalgias, according to the American College of Cardiology 1
• Bempedoic acid has oral administration, which is an advantage over injectable PCSK9 inhibitors, as noted by the American College of Cardiology 1

Other Non-Statin Medications

• Inclisiran, a newer PCSK9 inhibitor, is administered twice yearly and is beneficial for patients with adherence issues to PCSK9 mAbs, according to the American College of Cardiology 1
• Bile acid sequestrants provide 18-25% LDL-C reduction but have limited use due to poor tolerability, as reported in Arteriosclerosis, Thrombosis, and Vascular Biology 2
• Specialized therapies, such as evinacumab and lomitapide, are available for homozygous FH, as recommended by the American College of Cardiology 1

Treatment Algorithms

• For patients with ASCVD who have not achieved ≥50% LDL-C reduction or LDL-C <55 mg/dL on maximally tolerated statin, the American College of Cardiology recommends adding ezetimibe as first-line non-statin therapy, then considering PCSK9 inhibitors, and finally bempedoic acid if additional lowering is needed 1
• For patients unable to tolerate statins who require LDL-C lowering, the American College of Cardiology recommends ezetimibe as first-line therapy, PCSK9 inhibitors for high-risk patients, and bempedoic acid as an additional option 1

Clinical Considerations

• The American College of Cardiology advises against delaying intensification of therapy when patients don't reach LDL-C goals on statins, and instead recommends promptly adding non-statin therapy rather than continuing to titrate statins beyond tolerability 1
• The American College of Cardiology suggests considering combination initiation of statin plus ezetimibe simultaneously for very high-risk patients requiring substantial LDL-C reduction 1
• The American College of Cardiology emphasizes the importance of monitoring adherence, recognizing statin intolerance, and considering cost implications when using non-statin medications 1
• Low LDL-C levels (<0.65 mmol/L or <25 mg/dL) do not increase adverse events, even with long-term treatment, and there is no evidence of harmful effects on steroid hormone production, enterohepatic circulation of bile acids, or neuronal function with very low LDL-C levels, as reported by the European Heart Journal 6

Medication Comparison